VK2735 — EU research guide.

What is VK2735?

VK2735 is an investigational dual agonist of the GLP-1 and GIP receptors developed by Viking Therapeutics — the same dual-incretin mechanism class as tirzepatide. It is being developed in two formulations: a once-weekly subcutaneous injection and a once-daily oral tablet, with the goal of covering both the injectable and oral obesity markets with one molecule.

What does the research show?

In a Phase 2 study of the subcutaneous formulation (VENTURE), VK2735 produced mean weight loss of up to ~14.7% over 13 weeks, with the weight-loss curve still declining at the end of dosing (no plateau). The oral tablet's Phase 2 VENTURE-Oral trial (reported August 2025) met its primary and secondary endpoints, with up to ~12.2% mean weight loss from baseline at 13 weeks, though a notable dropout rate was discussed by analysts. The subcutaneous programme has advanced into Phase 3 (VANQUISH-1 and VANQUISH-2). As of mid-2026 VK2735 is not approved by any regulator.

EU legal status

Not approved in the EU. VK2735 is an investigational pharmaceutical owned by a single developer; it is not a generic research peptide and has no legitimate consumer or research-supply route. Material sold under this name on the gray market cannot be assumed to be authentic VK2735.